BLGO vs. SLI, ARQ, TSE, ADUR, LNZA, VGAS, ORGN, ZTEK, ALTO, and AMTX
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include Standard Lithium (SLI), ARQ (ARQ), Trinseo (TSE), Aduro Clean Technologies (ADUR), LanzaTech Global (LNZA), Verde Clean Fuels (VGAS), Origin Materials (ORGN), Zentek (ZTEK), Alto Ingredients (ALTO), and Aemetis (AMTX). These companies are all part of the "chemicals" industry.
BioLargo vs.
Standard Lithium (NYSE:SLI) and BioLargo (NASDAQ:BLGO) are both small-cap oils/energy companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
16.8% of Standard Lithium shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 3.7% of Standard Lithium shares are owned by insiders. Comparatively, 20.3% of BioLargo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, BioLargo had 1 more articles in the media than Standard Lithium. MarketBeat recorded 1 mentions for BioLargo and 0 mentions for Standard Lithium. Standard Lithium's average media sentiment score of 0.00 equaled BioLargo'saverage media sentiment score.
Standard Lithium has a net margin of 0.00% compared to BioLargo's net margin of -11.45%. Standard Lithium's return on equity of -11.52% beat BioLargo's return on equity.
Standard Lithium currently has a consensus target price of $3.95, suggesting a potential upside of 182.14%. Given Standard Lithium's stronger consensus rating and higher probable upside, equities research analysts plainly believe Standard Lithium is more favorable than BioLargo.
Standard Lithium has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, BioLargo has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
BioLargo received 109 more outperform votes than Standard Lithium when rated by MarketBeat users. However, 100.00% of users gave Standard Lithium an outperform vote while only 60.99% of users gave BioLargo an outperform vote.
Standard Lithium has higher earnings, but lower revenue than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Standard Lithium, indicating that it is currently the more affordable of the two stocks.
Summary
Standard Lithium beats BioLargo on 12 of the 16 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
This page (NASDAQ:BLGO) was last updated on 2/22/2025 by MarketBeat.com Staff
